Covers how the two drugs differ, why compounders face limits now that shortages are over, and Tennessee warnings about counterfeit shots sold online.
Recap by typeshit. Full story at The Tennessean.
A short clip from obesity doctor Nadolsky with his three pointers for people about to begin GLP-1 treatment. The details are in the video.
A general explainer on how GLP-1 receptor agonists affect blood sugar and appetite, with advice on support while taking them.
A sponsored-style look at compounded tirzepatide and semaglutide through telehealth firm Mochi Health, noting compounded drugs aren't FDA approved for safety or quality.
Among the items: Walmart plans free GLP-1 diabetes drugs for employees in 2027, and Verdiva Bio dropped a phase II oral GLP-1 study citing market changes.
Ingredient makers tell Nutrition Insight that companion products need trial evidence and careful claims, with HTBA pointing to fatigue on treatment.
12:50
Alex Wallace, who bills himself as a peptide expert, gives his response to what Dr. Mike has said about peptides. Details beyond the title are thin.
Loading…